# RYZUMVI (ryzumvi) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/ryzumvi

> The FDA approved RYZUMVI (ryzumvi), sponsored by Opus Genetics, Inc. (IRD), on November 5, 2026 for presbyopia in adults.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | RYZUMVI (ryzumvi) |
| Codes |  |
| Sponsor | Opus Genetics, Inc. (IRD) https://sec-api.dev/companies/ird/catalysts |
| Indications | [presbyopia in adults](https://sec-api.dev/indications/presbyopia-in-adults) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Sep 2023: FDA approval

- Status: completed, approved. Date confidence: month.
- First seen 2025-11-06, last confirmed 2025-11-06.
- SEC prospectus (424B) (accession 0001140361-25-040671): "In September 2023, we announced FDA approval of POS under the brand name RYZUMVI™ for the treatment of RM; for this approval we received a $10 million milestone payment under the Nyxol License Agreement." https://www.sec.gov/Archives/edgar/data/1228627/000114036125040671/ny20058362x1_424b5.htm

### November 5, 2026: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: presbyopia in adults.
- First seen 2026-11-05, last confirmed 2026-11-05.
- Press release filed with the SEC (EX-99) (accession 0001792044-26-000053): "•In October, the Company announced that the FDA approved RYZUMVI® (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia in adults." https://www.sec.gov/Archives/edgar/data/1792044/000179204426000053/exhibit991-3q26earningsrel.htm

## Same indication

- [LNZ100](https://sec-api.dev/pdufa/lnz100) (LENZ)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/ryzumvi.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "RYZUMVI (ryzumvi) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/ryzumvi

```bibtex
@misc{secapidev_pdufa_ryzumvi_20261116,
  title        = {RYZUMVI (ryzumvi) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/ryzumvi}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_ryzumvi_20261116","title":"RYZUMVI (ryzumvi) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/ryzumvi","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
